Nitrogen ( DrugBank: Nitrogen )


5 diseases
IDDisease name (Link within this page)Number of trials
5Progressive supranuclear palsy1
6Parkinson disease1
17Multiple system atrophy1
211Hypoplastic left heart syndrome1
299Cystic fibrosis1

5. Progressive supranuclear palsy


Clinical trials : 89Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

6. Parkinson disease


Clinical trials : 2,307Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

17. Multiple system atrophy


Clinical trials : 119Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

211. Hypoplastic left heart syndrome


Clinical trials : 22Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,695Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries